Shukra Pharmaceuticals has announced plans to invest ₹587 crore in a state of the art medical devices manufacturing facility in Uttar Pradesh, marking one of the largest single investments in the sector in the state. The project, to be located in the Jewar Bulandshahr industrial corridor, will focus on producing high-precision consumables, surgical instruments, diagnostic devices, and implants aiming to create over 2,500 direct jobs and position Uttar Pradesh as a key node in India’s growing medtech manufacturing ecosystem.
Glimpse:
The announcement, made on January 24, 2026, follows the company’s receipt of Letters of Comfort from the Uttar Pradesh government under its industrial promotion policies. The facility will span approximately 50 acres and include cleanrooms, automated assembly lines, R&D labs, and quality testing infrastructure compliant with global standards (US FDA, CE, ISO 13485). Production is expected to commence in phases starting late 2027, targeting both domestic demand and export markets in Southeast Asia, Africa, and the Middle East.
Shukra Pharmaceuticals, a fast emerging player in India’s medical devices sector, has committed ₹587 crore to build a large-scale manufacturing plant in Uttar Pradesh, reinforcing the state’s ambition to emerge as a major hub for medtech production. The investment was formally declared on January 24, 2026, following detailed discussions with the Uttar Pradesh Industrial Development Authority (UPIEDA) and the state’s Department of Medical, Health and Family Welfare.
The proposed facility will be located in the rapidly developing Jewar Bulandshahr industrial corridor, benefiting from proximity to the upcoming Noida International Airport, the Yamuna Expressway, and major logistics hubs. Spread across roughly 50 acres, the plant will feature Class 100,000 and Class 10,000 cleanrooms, fully automated injection moulding and assembly lines, dedicated R&D and prototyping centres, and in-house validation labs to meet stringent international quality requirements.
The product portfolio will span high-demand categories including disposable surgical consumables (syringes, IV sets, catheters, surgical drapes), precision orthopaedic implants, diagnostic disposables (blood collection tubes, rapid test kits), and select minimally invasive surgical instruments. The facility is designed with scalability in mind, with initial capacity targeting 500–700 million units annually and built-in flexibility for future expansion into biologics packaging and advanced wound care products.
The Uttar Pradesh government has extended significant incentives under its Industrial Investment & Employment Promotion Policy, including land at subsidised rates, capital subsidy of up to 25%, stamp duty exemptions, electricity duty waivers for 10 years, and SGST reimbursement for seven years. Shukra has committed to creating over 2,500 direct jobs (engineers, technicians, quality professionals, and support staff) and thousands more indirectly through local vendor development and logistics.
Amit Shukla, Founder & Managing Director of Shukra Pharmaceuticals, said: “Uttar Pradesh offers the perfect combination of policy support, land availability, skilled manpower, and strategic location. This facility will not only meet surging domestic demand for quality medical devices but also enable us to compete aggressively in global export markets while contributing to India’s self reliance in critical healthcare products.”
The project aligns with the national Production Linked Incentive (PLI) scheme for medical devices and the state’s broader industrialisation drive. It is expected to reduce India’s reliance on imported consumables and devices, lower healthcare costs, and generate substantial export revenue as Shukra targets markets in Africa, Southeast Asia, and Latin America.
Site preparation and regulatory clearances are already underway, with groundbreaking anticipated in mid-2026 and phased commercial production starting by late 2027. The facility is designed to achieve full US FDA and CE compliance from day one, positioning Shukra as a reliable global supplier.
“This investment is more than a factory it is a commitment to building India’s next-generation medtech capabilities right here in Uttar Pradesh, creating jobs, reducing import dependence, and making quality healthcare devices more affordable and accessible.”
By
HB Team
